克拉屈滨联合低剂量阿糖胞苷和粒细胞集落刺激因子治疗老年/无法耐受强化疗的难治/复发急性髓系白血病
- 1 北京协和医学院中国医学科学院血液病医院(中国医学科学院血液学研究所),天津 300020
- 2 血液与健康全国重点实验室,天津 300020
- 3 天津医学健康研究所,天津 301600
摘要
Cladribine combined with low-dose cytarabine and granulocyte colony-stimulating factor in older/unfit refractory/relapsed acute myeloid leukemia
- 1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China
- 2 State Key Laboratory of Experimental Hematology, Tianjin 300020, China
- 3 Tianjin Institute of Health Science, Tianjin 301600, China
Abstract
Objective CLAG (cladribine+cytarabine+granulocyte colony-stimulating factor) is recommended as one of the first-line salvage treatment for refractory/relapsed acute myeloid leukemia (R/R AML) patients. However, the toxicity limits its usage in older and unfit patients. Thus, we explored the feasibility of the regimen consisting of cladribine, low-dose cytarabine and granulocyte colony-stimulating factor (miniCLAG) in unfit R/R AML patients. Methods 16 older/ unfit R/R AML patients treated with the miniCLAG regimen from August 2022 to April 2025 were retrospectively analyzed. All of them received at least one course of miniCLAG. The regimen comprised cladribine 5 mg/m2 from day 1 to day 5 intravenously, cytarabine 20 mg q12h from day 1 to day 10 subcutaneously and granulocyte colony-stimulating factor (G-CSF) 300 μg/d from day 0 to day 10 subcutaneously (discontinued if WBC >20×109/L). Results The median age of our cohort was 60 years old with 50% aged 60 or older. The complete remission (CR)/CR with incomplete hematologic recovery (CRi) rate was 37. 5% , without treatment-related death. The median overall survival wasn't reached and the estimated 1-year overall survival was 85. 94% [95% confidence interval (CI): 69. 49%~100%]. The median relapse-free survival was 293 days (95% CI: 246 days-NA). AML without core-binding factor fusion protein gained longer overall survival under this regimen. Conclusion The miniCLAG regimen may provide considerable efficacy with acceptable toxicity to the refractory/relapsed unfit AML patients, especially for those without core-binding factor fusion protein.
